Updated on 24 June 2013
Experts however believe that Myriad's competitors would have some catching up to do as the company has tons of data that it has collected from two decades of providing the testing almost exclusively. Leading biotechnology and intellectual property lawyer, Mr Kevin Noonan has said prominent US publications, "Myriad has a 15-year head start on everybody. They started this. They have all the relationships with everybody. They are still going to be the gold standard."
Many experts however fear that the decision perhaps will give investors little reason to back the development of novel tests if there is no guarantee that they can recoup their funding during a period of patent exclusivity. Further the fear of protecting innovation still lurks large over the industry that has breathed an initial sigh of relief post the verdict.